Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 5.51 USD 12.68% Market Closed
Market Cap: 307.1m USD

Wall Street
Price Targets

FHTX Price Targets Summary
Foghorn Therapeutics Inc.

Wall Street analysts forecast FHTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FHTX is 10.78 USD with a low forecast of 4.04 USD and a high forecast of 14.7 USD.

Lowest
Price Target
4.04 USD
27% Downside
Average
Price Target
10.78 USD
96% Upside
Highest
Price Target
14.7 USD
167% Upside
Foghorn Therapeutics Inc. Competitors:
Price Targets
BEAM
Beam Therapeutics Inc
107% Upside
688520
Sinocelltech Group Ltd
25% Downside
TRDA
Entrada Therapeutics Inc
176% Upside
ELUT
Elutia Inc
211% Upside
688235
Beigene Ltd
28% Upside
ALT
Altimmune Inc
370% Upside
302440
SK Bioscience Co Ltd
18% Downside
TWST
Twist Bioscience Corp
35% Upside

Revenue
Forecast

Revenue Estimate
Foghorn Therapeutics Inc.

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 3 years is 24%.

N/A
Past Growth
24%
Estimated Growth
Estimates Accuracy
-28%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Foghorn Therapeutics Inc.

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Foghorn Therapeutics Inc.

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-25%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FHTX's stock price target?
Price Target
10.78 USD

According to Wall Street analysts, the average 1-year price target for FHTX is 10.78 USD with a low forecast of 4.04 USD and a high forecast of 14.7 USD.

What is Foghorn Therapeutics Inc.'s Revenue forecast?
Projected CAGR
24%

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 3 years is 24%.

Back to Top